

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
10
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
30
41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser
50
61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Thr His Thr Ile
70
81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
90
101 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
110
121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
130
141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
150

FIG. 13




FIG. 14A




FIG. 14B

1 Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly

41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu GLY Leu Tyr Leu Ile Tyr Ser

61 Gln Val Leu Phe Lys GLY Gln GLY Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile

81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro

101 Cys Gln Arg Glu Thr Pro Glu GLY Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu

121 GLY Gly val Phe Gln Leu Glu Lys GLY Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp

141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu

100 50 70 90 110 130 150

FIG. 15

Docket No.: 0975.1005-038

Title: Anti-TNF Antibodies and Peptides...

Inventors: Junming Le, *et al.*

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTGAGTCCAGGAGAAAGAGTCAGT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTGCAGGCCAGTCAGTCGTTGGCTCAAGCATTCCACTGGTATCAGCAAAGAACAA
PheSerCysArgAlaSerGlnPheValGlySerSerIleHistRptYrGlnGlnArgThr

AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCGGATCCCTTCC
AsnGlySerProArgLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTAGTGGCAGTCAGGACAGATTACTCTTAGCATCAACACTGTGGAGTCT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTACTGTCAAGAAAGTCATAAGCTGGCCATTACGTTCTGGCTCG
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTGGAAAGTAAAAA
GlyThrAsnLeuGluValLys

FIG. 16A

GAAGTGAAGCTTGAGGAGTCTGGAGGCCCTGGTGCACCGGATCCATGAAACTC
GluValLysLeuGluGluSerGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCCTGTGTTGCCTCTGGATTCACTAACCACTGGATGAACTGGGTCCGCCAGTCT
SerCysValAlaSerGlyPheSerAsnHisTrpMetAsnTrpValArgGlnSer
CCAGAGAAGGGCTTGAGTGGGTGCTGAAATTAGATCAAATCTATTAAATTCTGCACA
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCCGAGTCTGTGAAAGGGAGGTTCACAGAGATGATTCCAAAAGTGCT
His'TyrAlaGluSerValLysGlyArgPheThrIleSerArgaspSerLysSerAla
GTGTACCTGCCAATGACCGACTTAAGAACACTGGCGTTATTACTGTTCAGG
ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGCTACGACTACTGGGCCAAGGCACCACTCTCACAGTGTCC
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

FIG./ 16B




FIG. 18




FIG. 17




FIG. 20




FIG. 19




FIG. 22




FIG. 21




FIG. 23




FIG. 24




FIG. 25




FIG. 26B





FIG. 27






FIG. 28




FIG. 29




FIG. 30




FIG. 31A




FIG. 3IB




FIG. 31C




FIG. 32




FIG. 33A




FIG. 33B




FIG. 33D




FIG. 33C




FIG. 33F




FIG. 33E




FIG. 33H





FIG. 33G



* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ versus pre-infusion
† $p \leq 0.05$, †† $p \leq 0.01$, ††† $p \leq 0.001$ versus change in
placebo group

FIG. 34